Abstract: The invention is directed to 1-alkyl-9-bromohexagydro indoloquinolizium salts and a method for their use to increase blood circulation and decrease in blood vessel resistance.

Abstract: A novel process for preparing 11-bromo-vincaminic acid esters of the general formula ##STR1## wherein R.sup.1 and R.sup.2 each stand independently from each other for a C.sub.1-6 alkyl group, comprising the steps of treating a 1-alkyl-1-alkoxycarbonylethyl-octahydroindolo-quinolisine of the general formula ##STR2## wherein R.sup.2 is as defined above and R.sup.3 stands for a C.sub.1-6 alkyl group, with a brominating agent and treating the resulting isomeric mixture of the bromo-derivatives with an alkaline agent or treating the corresponding 14-oxo-E-homo-eburnane being unsubstituted in ring A with a brominating agent and nitrosating the resulting 11-bromo-14-oxo-E-homo-eburnane of the general formula ##STR3## wherein R.sup.2 is as defined above, then subjecting the resulting 11-bromo-14-oxo-15-hydroxyimino-E-homoeburnanes to deoxyimination and treating the 14,15-dioxo-derivatives obtained with a base in an alcohol of the general formula R.sup.1 OH, wherein R.sup.1 is as defined above.

Abstract: Vasodilating octahydro-indolo[2,3-a]quinolizine derivatives of the formula ##STR1## wherein Q is hydrogen or an A--CH.sub.2 --CH.sub.2 -- group and A is cyano or --COOR, wherein R is C.sub.1-6 alkyl.

Abstract: Piperazine derivatives having the formula (I) ##STR1## wherein R.sub.1 is C.sub.1-5 alkyl group which can have a phenyl, trimethoxyphenyl, phenoxy, methoxy-cyclohexyl or heptamethyleneimino substituent on the terminal carbon atom, allyl, phenyl which can have one or more halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trihalomethyl or allyl substituents, or C.sub.2-5 alkoxycarbonyl;R.sub.2 is hydrogen or C.sub.1-4 alkyl; andR.sub.3 is furyl or a C.sub.5-6 cycloalkyl having a C.sub.1-4 alkoxy substituent, and acid addition salts or quaternary salts thereof with anti-arrhythmic and coronary dilatating pharmaceutical effects.

Abstract: Novel Angiotensin II peptides of the formula:X-Arg-Val-Tyr-Ile-His-Pio-Ywhere X is hydroxyacetyl or .alpha.-hydroxypropyl and Y is leucyl, isoleucyl, alanyl or threonyl or an acid addition salt or a complex thereof are disclosed and a process for the preparation thereof are disclosed having the ability to lower renal hypertension.

Abstract: The invention relates to new 3-amino-17a-aza-D-homo-5.alpha.-androstane derivatives of the general formula I ##STR1## wherein R.sub.1 represents a methylene or an >N--CH.sub.3 group, and n stands for 1 or 2, and the acid addition salts and the quaternary salts of the general formula ##STR2## thereof, wherein R.sub.2 stands for an alkyl or alkenyl group having from 1 to 4 carbon atoms, and A represents a halogen atom, provided that if R.sub.1 stands for an >N--CH.sub.3 group, R.sub.2 is attached to the nitrogen of that >N--CH.sub.3 group. The new compound possess a non-polarizing neuromuscular blocking activity and have a short activity period.

Abstract: Ulcer production in animals is prevented during prolonged antiphlogistic treatment with ulcerogenic quantities of indomethacin by using it in a composition of 1 part of indomethacin to 7.5 to 25 parts, preferably 10 parts by weight of a salicylate. Indomethacin is the most potent ulcerating compound among approved non-steroid antiinflammatory agents.

Abstract: New 2-amino-cyclopent-1-ene-thiocarboxylic acid-disulfides of the general formula (I), ##STR1## wherein R is hydrogen, a C.sub.1-6 alkyl group having optionally a C.sub.1-4 alkoxy, hydroxy, carboxy and/or amino substituent, a C.sub.2-4 alkenyl group, a C.sub.3-8 cycloalkyl group or phenyl group, are prepared by oxidizing the respective 2-amino-cyclopent-1-ene-dithiocarboxylic acids of the general formula (II), ##STR2## wherein R is as defined above. The new compounds of the general formula (I) and their salts exert dopamine-.beta.-hydroxylase inhibiting effects and can be applied in the therapy.

Abstract: A method of treating mammalian noradrenaline malfunctions or dysfunction or effecting dopamine-.beta.-hydroxylase inhibition comprises administering an effective dose of an acid derivative of the formula (I), ##STR1## wherein R is C.sub.2-4 alkenyl, C.sub.3-8 cycloalkyl, benzyl or C.sub.1-6 alkyl which has a C.sub.1-4 alkoxy or a hydroxy substituent, or C.sub.2-6 alkyl with a carboxy and/or amino substituent, or C.sub.5 - or C.sub.6 -unsubtituted alkyl.

Abstract: Ulcer production in animals is prevented during prolonged antiphlogistic treatment with ulcerogenic quantities of phenylbutazone by using it in a composition of 1 part of antiphlogistic to 0.2 to 50 parts by weight of alkali metal salicylate.

Abstract: 3-[4-(2'-Pyridyl)-piperazin-1-yl]-1-(3,4,5-trimethoxybenzoyloxy)-propane or a pharmaceutically acceptable acid-addition salt thereof in a composition with anti-arrhythmic activity.

Abstract: New hydroxymethyl-pyridine esters of the formula (I) ##STR1## wherein R represents a 9-xanthenyl group or a phenyl group substituted by a halogen atom or a trifluoromethyl group or by an alkyl or alkoxy group, either having 1 to 4 carbon atoms, and pharmaceutically acceptable acid addition salts and quaternary salts thereof are prepared by acylating the corresponding hydroxymethyl pyridines with a carboxylic acid of the formula R--COOH, or with a reactive derivative thereof, and, if desired, converting the obtained product of the formula I into a pharmaceutically acceptable acid addition salt or quaternary salt thereof. The new compounds exert beneficial effects on functional disorders of the heart.

Abstract: Angiotensin II analog of the formula IX-Arg-Val-Tyr-Ile-His-Pro-Y (I)whereinX is a radical derived from an aliphatic .alpha.-aminooxy-carboxylic acid andY is a radical derived from an aliphatic .alpha.-amino-carboxylic acid,and acid addition salts and complexes thereof with antagonistic properties useful in the diagnosis and treatment of hypertensions depending on renin.

Abstract: 2-Amino-cyclopent-1-ene-1-dithiocarboxylic acid derivatives of the formula, ##STR1## wherein R is C.sub.2-4 alkenyl, or C.sub.1-6 alkyl group having optionally a C.sub.1-4 alkoxy, hydroxy, carboxy and/or amino substituent, with the proviso that if R is an unsubstituted alkyl group, this group contains at least 5 carbon atoms, are prepared by reacting 2-amino-cyclopent-1-ene-1-dithiocarboxylic acid or a salt thereof with an amine of the formula,R--NH.sub.2 (II)wherein R is as defined above. The new compounds of the invention exert dopamine-.beta.-hydroxylase inhibiting effects.

Abstract: New 2-amino-cyclopent-1-ene-thiocarboxylic acid-disulfides of the formula, ##STR1## wherein R is a C.sub.1-6 alkyl group having optionally a C.sub.1-4 alkoxy, hydroxy, carboxy and/or amino substituent, a C.sub.2-4 alkenyl group, or a C.sub.3-8 cycloalkyl group, are prepared by oxidizing the respective 2-amino-cyclopent-1-ene-dithiocarboxylic acids of the formula, ##STR2## wherein R is as defined above. The compounds of the formula (I) exert dopamine-.beta.-hydroxylase inhibiting effects and can be applied in therapy.

Abstract: Curare-type salts of the formula ##STR1## wherein Ac is an alkyl carbonyl group containing 1 to 4 carbon atoms in the alkyl moiety and one ofR.sub.1 and R.sub.2, is a methylene group and the other is a group of the formula >N--R.sub.2 wherein R.sub.2 is an alkyl group containing 1 to 3 carbon atoms,A is halogen andR.sub.3 is an alkyl group containing 1 to 4 carbon atoms, or an alkyl group; anda process for the preparation thereof are disclosed.

Abstract: New pharmacologically active octahydro-indolo[2,3-a]quinolizine derivatives of the formula ##STR1## wherein Q is hydrogen or an A--CH.sub.2 --CH.sub.2 -- group and A is cyano or -COOR, wherein R is C.sub.1-6 alkyl are prepared by reacting 2,3,4,6,7,12-hexahydro-indolo[2,3-a]quinolizine with a compound of the formula CH.sub.2 .dbd.

Abstract: The new compound vincane of the formula ##STR1## is prepared by the reduction or reductive dehydratation, respectively, a compound of the formula ##STR2## wherein A.about.B represents the group --CH.dbd.CH-- or ##STR3## i.e. of vincamenine or of vincanol.

Abstract: The invention relates to novel piperazine derivatives having the formula (I), ##STR1## wherein R.sub.1 represents a C.sub.1-5 alkyl group having optionally a phenyl, trimethoxyphenyl, phenoxy, methoxy-cyclohexyl or heptamethyleneimino substituent on the terminal carbon atom, allyl group, a phenyl group having optionally one or more halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trihalomethyl or allyl substituent(s), or a C.sub.2-5 alkoxycarbonyl group,R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group, andR.sub.3 represents furyl group, 9-xanthenyl group or a C.sub.5-6 cycloalkyl group having a C.sub.1-4 alkoxy substituent,Or acid addition salts or quaternary salts thereof.The invention also relates to pharmaceutical compositions containing the above compounds, furthermore to a process for the preparation of the novel compounds and pharmaceutical compositions.The novel compounds according to the invention possess anti-arrhythmic and coronary dilatating effects.

Abstract: A compound of the formula (I) ##STR1## wherein X stands for a hydrogen atom, an optionally substituted aliphatic or aromatic sulfonyloxy group, a thiocyanato group, an azido group or an amino group optionally mono- or disubstituted by aliphatic, cycloaliphatic, aromatic or araliphatic hydrocarbon groups, acyl, alkyloxycarbonyl, cycloalkyloxycarbonyl, aryloxycarbonyl, aralkyloxycarbonyl, aminocarboimido groups or the substituents of the said amino group may form with the nitrogen atom thereof a five-, six- or seven-membered saturated or unsaturated heterocyclic ring optionally containing a further nitrogen, oxygen or sulfur hetero atom, and a quaternary salt or acid addition salt thereof. The compounds are useful in the treatment of arteriosclerosis and high blood pressure.